A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant

Clinical study designed to collect blood for research purposes in patients after hematopoietic stem cell transplantation (HSCT) or in patients with a medical condition where the blood cells production is impaired. The blood samples will be used to study the role of Interferon gamma (IFNɣ) in graft failure or impairment of hematopoietic stem cell proliferation. The IFNɣ signature will be assessed by measuring primarily IFNɣ and C-X-C Motif Chemokine Ligand 9 (CXCL9).

Study Overview

• Status: Terminated
• Conditions: Graft Failure
• Intervention / Treatment: Procedure: blood collection

Detailed Description

This clinical study is designed to investigate IFNγ activity in two cohorts of patients.

• First group will include patients post HSCT at risk of graft failure (GF) based on their underlying diseases and on the transplant procedure.
• Second group will contain patients with conditions where HSC proliferation is impaired (e.g. aplastic anemia) and with matched controls (healthy volunteers (HV) samples collected outside this clinical protocol).

IFNɣ activity will be assessed by measuring IFNγ and CXCL9 in serum.

For HSCT cohort, the following sampling time points are required: on day -7, pre HSCT on day 0, 1, 3, 5, 9, 13, 17, 21, 28, 31, 38 and one additional sample at the time when primary or secondary GF is suspected if not on the planned schedule. In addition, the following time points are recommended: day 7, 11, 15, 19, 24, 35, 42. It is also suggested to collect a sample when Graft vs Host Disease (GVHD) is diagnosed during any visit that the patients will attend as part of his/her standard treatment during the first 100 days post-transplant. The patient will be followed up until around day 100 post-transplant. This follow up will consist of capturing HSCT outcome information from patient hospital records around day 100.

For IHSCP cohort pre-transplant, it is recommended that, one sample per patient at the time of diagnosis (if possible not more than 1 week from the date of diagnosis) is collected. Age/sex matched control samples should be collected from healthy volunteers or patients with malignant disease outside of this protocol after appropriate consent.

Different sets of data will be collected for the HSCT and IHSCP cohorts respectively as described below:

Data collected for both cohorts

• Age and sex
• Inflammatory markers
• IFNɣ
• CXCL9
• Other potential relevant exploratory biomarkers
• Diagnosis
• Date of disease diagnosis
• Relevant medical history
• Date and time of sample collection

Data collected for HSCT cohort only

• Laboratory parameters assessed at the site laboratory on the date of sample collection and between collection dates when available:
• Absolute neutrophile count (ANC) and Platelets will be measured as per the schedule of assessment, if possible when routine monitoring of patient health is conducted
• Ferritin and Chimerism data will be collected when available (if measured as per site routine practice)
• Concomitant medications at the time of sample collection and between collection dates
• Presence of infection at the time of sample collection with the date of onset
• Presence of donor specific antibodies (DSA)
• Transplant information
• Date of start of conditioning
• Type of conditioning (Reduced Intensity Conditioning (RIC) / Myeloablative Conditioning (MAC) / Non-myeloablative Conditioning (NMAC) and medications
• Transplant details (donor type, degree of match, transplant manipulation, stem cell source)
• Date of transplant
• Date of primary / secondary GF or of confirmed engraftment
• GVHD with the date of onset
• Post-transplant treatment and date (Donor Lymphocyte Infusion (DLI), Stem Cell (SC) boost, growth factor, GVHD prophylaxis, second HSCT procedure)

Data collected for IHSCP cohort only

• Disease severity
• In addition, the following data will be recorded for pediatric patients up to 18 years old, if available:
• PNH clones
• History of hepatitis
• Karyotype

Study duration:

The study will be conducted, until the required number of patients is recruited.

• HSCT cohort: At patient level, the study will last about 100 days from pre-transplant blood collection to last follow up data collection around day 100 post HSCT, matching the standard HSCT patient care
• IHSCP cohort: At patient level the study will last 1 day.

• Study Type: Observational
• Enrollment (Actual): 101

Contacts and Locations

Study Locations

• Belgium
  • Brussels, Belgium, 1200
    • Cliniques Universitaires Saint-luc
  • West-Vlaanderen
    • Roeselare, West-Vlaanderen, Belgium, 8800
      • Algemeen Ziekenhuis Delta - Campus Rumbeke
• France
  • Basse-Normandie
    • Caen cedex 9, Basse-Normandie, France, 14033
      • Hôpital Côte De Nacre
  • Bretagne
    • Rennes cedex 9, Bretagne, France, 35033
      • Hôpital Pontchaillou
  • Franche-Comte
    • Besançon Cedex, Franche-Comte, France, 25030
      • Centre Hospitalier Régional et Universitaire de Besançon - Hôpital Jean-Minjoz
  • Ile De France
    • Paris, Ile De France, France, 75010
      • Hopital Saint-Louis
  • Ile-de-France
    • Paris, Ile-de-France, France, 75019
      • Hôpital Universitaire Robert-Debré
  • Lorraine
    • Vandœuvre-lès-Nancy, Lorraine, France, 54511
      • Hopitaux de Brabois
  • Maine Et Loire
    • Angers Cedex 9, Maine Et Loire, France, 49933
      • Centre Hosptitalier Universitaire d'Angers
  • Nouvelle Aquitaine
    • Pessac, Nouvelle Aquitaine, France, 33604
      • Hôpital Haut-Lévêque
  • Provence Alpes Cote d'Azur
    • Montpellier, Provence Alpes Cote d'Azur, France, 34090
      • Hopital Arnaud de Villeneuve
    • Montpellier Cedex 5, Provence Alpes Cote d'Azur, France, 34295
      • Hopital Saint-Eloi
  • Rhone-Alpes
    • La Tronche, Rhone-Alpes, France, 38700
      • Centre Hospitalier Universitaire Grenoble Alpes
  • Rhône
    • Clermont-Ferrand, Rhône, France, 63003
      • Centre Hospitalier Universitaire Estaing
• Germany
  • Baden-Württemberg
    • Tübingen, Baden-Württemberg, Germany
      • Universitätsklinikum Tübingen
• Italy
  • Avellino, Italy, 83100
    • Azienda Ospedaliera San Giuseppe Moscati
  • Genova, Italy, 16147
    • Instituto Giannina Gaslini
  • Milano, Italy, 20132
    • Ospedale San Raffaele
  • Pavia, Italy, 27100
    • Fondazione IRCCS Policlinico San Matteo
  • Torino, Italy, 10126
    • Ospedale Regina Margherita
  • Lombardia
    • Roma, Lombardia, Italy, 00165
      • Ospedale Pediatrico Bambino Gesù - Roma - Gianicolo
• Netherlands
  • Utrecht, Netherlands, 3584 CS
    • Prinses Maxima Centrum Kinderoncologie
• United Kingdom
  • London, United Kingdom, SW3 6JJ
    • The Royal Marsden Hospital - London
  • London, United Kingdom, W12 0HS
    • Imperial College Healthcare NHS Trust NHS Trust
  • Wales
    • Cardiff, Wales, United Kingdom, CF14 4XW
      • Cardiff and Vale University Health Board

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

• Patients post HSCT at risk of graft failure based on their underlying diseases and on the transplant procedure.
• Patients with conditions where HSC proliferation is impaired (e.g. aplastic anemia) and with respective controls (healthy volunteers (HV)).

Description

Inclusion Criteria:

• The patient must have consented to the use of their clinical data and biological samples for research investigations.

• In HSCT cohort:

  • Patients with underlying:

    i. non-malignant hematological disease (e.g. autoimmune and metabolic disorders, aplastic anemia, Sickle cell anemia, Fanconi anemia, Diamond-blackfan anemia, thalassemia, osteopetrosis, Wiskott-Aldrich syndrome, severe combined immunodeficiency) or ii. malignant disease with higher risk of GF, i.e. Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) with primary induction failure, second partial remission or relapse; Chronic Myeloid Leukemia (CML) in blastic phase (circulating blast or blast above 5% in biopsy); Non Hodgkin and Hodgkin Lymphoma and multiple myeloma with primary induction failure, second partial remission or relapse, myelodysplastic syndromes (MDS) and myeloproliferative disorders (MPD) with splenomegaly, myelofibrosis with portal hypertension pre-transplant, MDS/MPD overlap syndromes

  • and who received allogeneic HSCT and are at higher risk of graft failure based on at least one of the following criteria: i. Having received reduced intensity conditioning (RIC) or non myeloablative conditioning (NMA) combined with a non-malignant disease or having received graft from Bone Marrow (BM) ii. Ex vivo T cell depleted graft iii. Graft from mismatched unrelated donor or haploidentical donor iv. Graft from Umbilical Cord Blood (UCB)

• In the IHSCP cohort:

  • Patients with IHSCP pre-transplant (e.g. aplastic anemia)

Exclusion Criteria:

• HLH patients
• Body weight < 10kg

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
HSCT - Hematopoetic Stem Cell Proliferation; Patients who received hematopoietic stem cell transplant	Procedure: blood collection; Blood samples will be collected as per protocol defined schedule. There is no investigation drug in this study.
IHSCP - Impaired HSC proliferation; Patients with impaired hematopoietic stem cell proliferation	Procedure: blood collection; Blood samples will be collected as per protocol defined schedule. There is no investigation drug in this study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
HSCT cohort: IFNγ signature pre-and post-transplant	IFNγ, CXCL-9 and exploratory biomarkers in serum samples	Day (-7) to day 100
HSCT cohort: Relationship between IFNγ and the risk of graft failure	IFNγ and CXCL-9 in serum samples	Day (-7) to day 100
HSCT cohort: Relationship between IFNγ and the occurrence of GVHD	IFNγ and CXCL-9 in serum samples	Day (-7) to day 100
IHSCP cohort: IFNγ signature pre-transplant	IFNγ, CXCL-9 and exploratory biomarkers in serum samples	Day 1

Collaborators and Investigators

• Sponsor: Swedish Orphan Biovitrum
• Collaborators: PRA Health Sciences; BioMérieux; Cytel Inc.
• Investigators: Principal Investigator: Regis Peffault de Latour, MD, Hôpital Saint Louis Paris

Study record dates

Study Major Dates

• Study Start (Actual): November 16, 2020
• Primary Completion (Actual): August 31, 2022
• Study Completion (Actual): August 31, 2022

Study Registration Dates

• First Submitted: July 28, 2020
• First Submitted That Met QC Criteria: July 28, 2020
• First Posted (Actual): July 31, 2020

Study Record Updates

• Last Update Posted (Actual): October 21, 2022
• Last Update Submitted That Met QC Criteria: October 19, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Other Study ID Numbers: NI-0501-13

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No